4CMenB vaccine: all 51 studies that test it
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic DiseasesRecruitingNCT07252804Phase 4
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young AdultsRecruitingNCT07197762Phase 4
- Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender PersonsRecruitingNCT06832514Phase 4
- Meningococcal B Vaccine in Patients with AspleniaRecruitingNCT06025487Phase 2
- Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.RecruitingNCT04166656Phase 3
- Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of AgeCompletedNCT04893811Phase 4Results posted
- Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB VaccinationCompletedNCT04722003Phase 2Results posted
- A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy InfantsTerminatedNCT04645966Phase 2Results posted
- Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsCompletedNCT04502693Phase 3Results posted
- MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of AgeCompletedNCT04440163Phase 3Results posted
- Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis VaccineCompletedNCT04094883Phase 4Results posted
- Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)CompletedNCT04084769Phase 3Results posted
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedNCT03621670Phase 3Results posted
- A Sourcing Study to Collect Human Blood Samples From Healthy AdultsCompletedNCT03493919Phase 4Results posted
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.CompletedNCT03135834Phase 3Results posted
- Pharmacists as Immunizers to Improve Coverage and Provider/Recipient SatisfactionCompletedNCT02868970Phase 4Results posted
- Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.CompletedNCT02305446Phase 3Results posted
- Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in AdolescentsCompletedNCT02212457Phase 2Results posted
- Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.CompletedNCT02173704Phase 3Results posted
- Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy InfantsCompletedNCT02106390Phase 3Results posted
- A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.CompletedNCT01911221Phase 3Results posted
- A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 YearsCompletedNCT01830855Phase 3Results posted
- Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of AgeCompletedNCT01768117Phase 2Results posted
- Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1CompletedNCT01717638Phase 3Results posted
- Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 YearsCompletedNCT01423084Phase 3Results posted
- A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.CompletedNCT01352845Phase 3Results posted
- A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.CompletedNCT01323270Phase 2Results posted
- One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of AgeCompletedNCT01139021Phase 3Results posted
- Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same VaccineCompletedNCT01026974Phase 2Results posted
- Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12CompletedNCT00944034Phase 2/3Results posted
- Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old InfantsCompletedNCT00937521Phase 2Results posted
- Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization SchedulesCompletedNCT00721396Phase 2Results posted
- Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination SchedulesCompletedNCT00661713Phase 2/3Results posted
- Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk AdultsCompletedNCT00560313Phase 2Results posted
- Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in AdolescentsCompletedNCT00387725Phase 2Results posted
- A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)CompletedNCT06995430Phase 3
- BIYELA - Bexsero Immunisation in Young Women in AfricaActive, not recruitingNCT06446752Phase 3
- Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and AdolescentsCompletedNCT06128733Phase 1/2
- A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeActive, not recruitingNCT06113198Phase 4
- Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea InfectionsActive, not recruitingNCT05766904Phase 3
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria GonorrhoeaeCompletedNCT05294588Phase 2
- Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual MenActive, not recruitingNCT04415424Phase 3
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal InfectionCompletedNCT04350138Phase 2
- Gonococcal Vaccine Study in Key Populations in KenyaCompletedNCT04297436Not applicable
- Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk PopulationStatus unknownNCT03682939Phase 4
- Babies Born Early Antibody Response to Men B Vaccination: BEAR Men BCompletedNCT03125616Phase 4
- South Australian Meningococcal B Vaccine Herd Immunity StudyCompletedNCT03089086Phase 4
- Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young AdultsCompletedNCT02583412Phase 4
- Investigating Meningococcal Vaccines in AdultsCompletedNCT02398396Not applicable
- Investigating the Immune Response to 4CMenB in InfantsCompletedNCT02080559Phase 4
- Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy AdolescentsCompletedNCT00297817Phase 2